Organization

Takeda Pharmaceuticals USA, Inc.

1 abstract

Abstract

Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).

Org: Stanford University Medical Center, Stanford, CA, Takeda Development Center Americas, Inc., Lexington, MA, USA, Takeda Pharmaceuticals USA, Inc., Massachusetts General Hospital,